Appendix B: Sources of evidence considered by the Committee
A. The Evidence Review Group (ERG) report for this appraisal was prepared by Aberdeen HTA Group:
-
Kilonzo M, Hislop J, Elders A et al. Pazopanib for the first line treatment of patients with advanced and/or metastatic renal cell carcinoma (September 2010)
B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope. Organisations listed in I were also invited to make written submissions. Organisations listed in II gave their expert views on pazopanib by providing a written statement to the Committee. Organisations listed in I, II and III have the opportunity to appeal against the final appraisal determination.
I) Manufacturer/sponsor:
-
GlaxoSmithKline
II) Professional/specialist and patient/carer groups:
III) Other consultees:
-
Department of Health
-
NHS Waltham Forest
-
Welsh Assembly Government
IV) Commentator organisations (did not provide written evidence and without the right of appeal):
C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on pazopanib by providing oral evidence to the Committee.
-
Dr Thomas Powles, Senior Lecturer and Consultant, nominated by GlaxoSmithKline and Pfizer Ltd – clinical specialist
-
Dr David Chao, Consultant Medical Oncologist, nominated by Royal College of Physicians – clinical specialist
-
Jacqueline Lowe, nominated by Kidney Cancer UK – patient expert
-
Bill Savage, patient advocate, nominated by James Whale Fund for Kidney Cancer – patient expert
D. Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.
-
GlaxoSmithKline